In the pandemic’s initial dark days, physicians and patients and their families were desperate for effective COVID-19 treatments. They didn’t yet have monoclonal antibodies or antiviral pills to lessen the ravages of the disease, so many turned to a therapy more than a century old. At the very least, they […]
Findings from Johns Hopkins–led study support antibody-rich blood as an early treatment option The results of a nationwide, multicenter clinical trial led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health provide solid evidence for the use of plasma from convalescent patients—those who have recovered from the disease and whose […]
The FDA on Tuesday both limited and expanded the emergency use authorization (EUA) for convalescent plasma as a treatment for COVID-19. In its updated EUA, the agency restricted the use of high-titer COVID-19 convalescent plasma to immunocompromised patients, but stated that “these patients may be treated in outpatient or inpatient settings.” (Previously, use […]
